Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (k24 AR063120)
Received: 14 November 2018
Accepted: 2 January 2019
First Online: 16 January 2019
Ethics approval and consent to participate
: The study protocols for both SLS-I and II were approved by the local Institutional Review Boards, and written informed consent was obtained from all participants.
: Not applicable.
: Boehringer Ingelheim was not involved in directing the content of the manuscript and was only given the opportunity to review the manuscript for factual accuracy.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.